| Description |
1 online resource |
| Series |
Psychiatry- theory, applications, and treatments |
|
Psychiatry- theory, applications, and treatments series.
|
| Contents |
ANTIPSYCHOTIC DRUGS CLASSIFICATION, PHARMACOLOGY AND LONG-TERM HEALTH EFFECTS ; ANTIPSYCHOTIC DRUGS CLASSIFICATION, PHARMACOLOGY AND LONG-TERM HEALTH EFFECTS ; CONTENTS ; PREFACE ; Chapter 1 LONG-ACTING ANTIPSYCHOTICS: THE FACTS AND THE MYTHS FROM SYMPTOMS MANAGEMENT TO TARGETED TREATMENT ; ABSTRACT ; INTRODUCTION ; 1. ADHERENCE TO TREATMENT IN MENTAL DISORDERS: DEFINITIONS, BOUNDARIES AND MISCONCEPTIONS ; 1.1. From Compliance to Adherence to Treatment ; 1.2. The Factors Affecting Adherence to Treatments in Somatic Diseases |
|
1.3. Adherence to Treatment in Mental Disorders: From Low Insight to Recovery 2. HISTORICAL BACKGROUND ; 2.1. The Development of Long-Acting Antipsychotics in the 1960s Psychiatric Cultural Context ; 2.2. The Question of Polypharmacy vs. Monotherapy ; 2.3. An Overview of the Development of First Generation LAIs ; 3. LONG-ACTING FGAS: HISTORY, DEVELOPMENT AND PHARMACEUTICAL PROPERTIES ; 3.1. Fluphenazine Enanthate/Decanoate ; 3.2. Clopenthixol Enanthate and Zuclopenthixol Decanoate/Acetate ; 3.3. Flupenthixol Decanoate ; 3.4. Haloperidol/Bromperidol Decanoate |
|
3.5. Pipothiazine Palmitate/Undecylenate 3.6. Fluspirilene/Penfluridol ; 3.7. Perphenazine Enanthate/Decanoate ; 3.8. Oxyprothepin Decanoate, the LAI that came in from the Cold; 4. THE CHALLENGE OF THE 'LAST RESORT' TREATMENTS: NEW TECHNOLOGIES FOR THE SECOND GENERATION LAIS ; 4.1. Risperidone Long-Acting Injection ; 4.3. Paliperidone Palmitate ; 4.4. Olanzapine Pamoate ; 4.5. Aripiprazole, Long-Acting Injectable Formulation ; 5. THE UTILIZATION OF LAIS: CLINICAL PRINCIPLES OF BEST TREATMENT PRACTICE |
|
5.1. Support in the Community is Necessary to Tackle Non-Adherence to Treatments when Using LAIs 5.2. Practicioners' and Patients' Attitudes towards LAIs ; 5.3. The Treatment with LAIs might be Effectively Supported by Treatment Alliance and Effective Communication Strategies ; 5.4. More Benefits than Risks from the Treatment with Long-Acting Antipsychotics? ; 6. RESEARCH INDICATIONS ON LAIS: BEST EVIDENCE FROM REAL-WORLD PRACTICE ; 6.1. Introduction ; 6.2. Materials and Methods ; 6.2.1. The Catchment Area ; 6.2.2. Assessment of LAIs use in Portogruaro CMHC |
|
6.2.3. Characteristics of the Sample 6.3. Results ; 6.4. Discussion and Conclusion ; 7. THE NEW EVIDENCE STEMMING FROM RESEARCH ; 7.1. Forthcoming Antipsychotic Injections and other Long-Acting Formulations for Integrated Mental Health Treatments ; 7.1.1. Iloperidone Long-Acting Injection ; 7.1.2. Transdermal Olanzapine Patches ; 7.1.3. Transdermal Risperidone Patches ; 7.1.4. Aripiprazole Long-Acting Oral Formulation ; 7.1.5. Paliperidone Three-Month Long-Acting Injection ; 7.2. Long-Acting Drugs for New or Unusual Context ; 7.2.1. LAIs and First-Episode Psychoses |
| Notes |
"Nova biomedical." |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Description based on print version record and CIP data provided by publisher |
| Subject |
Antipsychotic drugs.
|
|
Antipsychotic Agents
|
|
MEDICAL / Pharmacology
|
|
Antipsychotic drugs
|
| Form |
Electronic book
|
| Author |
Aguilar, Mark L., editor
|
| LC no. |
2020677145 |
| ISBN |
1634844033 |
|
9781634844031 |
|
1634844181 |
|
9781634844185 |
|
